S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Battery Metal Nobody Told You About (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Battery Metal Nobody Told You About (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Battery Metal Nobody Told You About (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Battery Metal Nobody Told You About (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

Dr. Reddy's Laboratories (RDY) Earnings Date, Estimates & Call Transcripts

$69.78
-0.05 (-0.07%)
(As of 12/5/2023 ET)
Compare
Today's Range
$69.33
▼
$69.92
50-Day Range
$64.27
▼
$69.90
52-Week Range
$51.11
▼
$73.17
Volume
163,884 shs
Average Volume
241,306 shs
Market Capitalization
$11.64 billion
P/E Ratio
18.81
Dividend Yield
0.59%
Price Target
$70.00
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
Jan. 24Estimated
Actual EPS
(Oct. 27)
$1.07 Beat By $0.19
Consensus EPS
(Oct. 27)
$0.88
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

RDY Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RDY Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Dr. Reddy's Laboratories Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20231$0.57$0.57$0.57
20231$0.57$0.57$0.57
Q1 20241$0.71$0.71$0.71
Q2 20241$0.88$0.88$0.88
Q3 20241$0.87$0.87$0.87
Q4 20241$0.86$0.86$0.86
FY 20244$3.32$3.32$3.32
Q1 20251$1.10$1.10$1.10
Q2 20251$0.99$0.99$0.99
Q3 20251$1.00$1.00$1.00
Q4 20251$1.01$1.01$1.01
FY 20254$4.10$4.10$4.10
Q1 20261$1.03$1.03$1.03
Q2 20261$1.04$1.04$1.04

RDY Earnings Date and Information

Dr. Reddy's Laboratories last released its earnings data on October 27th, 2023. The reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.19. The business had revenue of $832.16 million for the quarter, compared to analysts' expectations of $825.94 million. Dr. Reddy's Laboratories has generated $3.71 earnings per share over the last year ($3.71 diluted earnings per share) and currently has a price-to-earnings ratio of 18.8. Earnings for Dr. Reddy's Laboratories are expected to grow by 5.96% in the coming year, from $3.86 to $4.09 per share. Dr. Reddy's Laboratories has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, January 24th, 2024 based off prior year's report dates.

Dr. Reddy's Laboratories Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
1/24/2024
Estimated)		------- 
10/27/2023Q2 2024$0.88$1.07+$0.19$1.07$825.94 million$832.16 million
7/26/2023Q1 2024$0.71$1.03+$0.32$1.03$790.67 million$820.20 million
5/10/2023Q4 2023$0.57$0.70+$0.13$0.70$763.37 million$766.00 million
1/25/2023Q3 2023$0.60$0.91+$0.31$0.91$769.25 million$818.00 million
10/28/2022Q2 2023$0.59$0.82+$0.23$0.82$763.28 million$775.00 million
7/28/2022Q1 2023$0.58$0.90+$0.32$0.90$767.00 million$660.00 million
5/19/2022Q4 2022-$0.53+$0.53$0.99-$717.00 million
1/28/2022Q3 2022-$0.57+$0.57$0.57-$715.00 million
10/29/2021Q3 2021$0.56$0.80+$0.24$0.80-$777.00 million
7/27/2021Q2 2021$0.55$0.46($0.09)$0.46$685.22 million$662.00 million
5/13/2021Q1 2021$0.51$0.46($0.05)$0.46-$646.00 million  
1/29/2021Q3 2021-$0.41+$0.41$0.80-$675.00 million












Dr. Reddy's Laboratories Earnings - Frequently Asked Questions

When is Dr. Reddy's Laboratories's earnings date?

Dr. Reddy's Laboratories has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, January 24th, 2024 based off last year's report dates. Learn more on RDY's earnings history.

Did Dr. Reddy's Laboratories beat their earnings estimates last quarter?

In the previous quarter, Dr. Reddy's Laboratories (NYSE:RDY) reported $1.07 earnings per share (EPS) to beat the analysts' consensus estimate of $0.88 by $0.19. Learn more on analysts' earnings estimate vs. RDY's actual earnings.

How much revenue does Dr. Reddy's Laboratories generate each year?

Dr. Reddy's Laboratories (NYSE:RDY) has a recorded annual revenue of $2.99 billion.

How much profit does Dr. Reddy's Laboratories generate each year?

Dr. Reddy's Laboratories (NYSE:RDY) has a recorded net income of $548 million. RDY has generated $3.71 earnings per share over the last four quarters.

What is Dr. Reddy's Laboratories's price-to-earnings ratio?

Dr. Reddy's Laboratories (NYSE:RDY) has a trailing price-to-earnings ratio of 18.81 and a forward price-to-earnings ratio of 18.08. The price/earnings-to-growth ratio is 2.06.

What is Dr. Reddy's Laboratories's EPS forecast for next year?

Dr. Reddy's Laboratories's earnings are expected to grow from $3.86 per share to $4.09 per share in the next year, which is a 5.96% increase.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NYSE:RDY) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -